Clovis Oncology, Inc. (NASDAQ:CLVS) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07 Submission of Matters to a Vote of Security Holders
The Annual Meeting of Shareholders (the Annual Meeting) of Clovis
Oncology, Inc. (the Company) was held on June8, 2017. At the
Annual Meeting, the shareholders of the Company voted on the
following two proposals and cast their votes as described below.
Proposal One
The individuals listed below were elected at the Annual Meeting
to serve a three-year term on the Companys Board of Directors.
|
For |
Withheld |
BrokerNon-Votes |
||||
|
Keith Flaherty, M.D. |
29,945,650 | 590,325 | 7,876,004 | |||
|
Ginger L. Graham |
29,915,559 | 620,416 | 7,876,004 | |||
|
Edward J. McKinley |
29,993,513 | 542,462 | 7,876,004 |
Proposal Two
Proposal two was to ratify the appointment of Ernst Young LLP as
auditors of the Company for fiscal year 2017, as described in the
proxy materials. This proposal was approved.
|
For |
Against |
Abstained |
||||
|
38,120,581 |
87,285 | 204,113 |
– 2 –
About Clovis Oncology, Inc. (NASDAQ:CLVS)
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b).